Foresite Capital Management IV, LLC

In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Foresite Capital Management IV, LLC reported 4 stock positions worth $108.8 million. Its top holding was Pharvaris (PHVS) at 77.5% of the portfolio, followed by Kura Oncology (KURA, 13.8%) and Lyell Immunopharma (LYEL, 4.9%). Compared with Q3 2024, it sold out of 1 and reduced 1. The biggest sale was an exit from Syndax Pharmaceuticals (SNDX).

Most Recent 13F
Q2 2026
Location
WEST HOLLYWOOD, CA
CIK
0001704132
Portfolio Value
$108.8M (Q4 2024)
SEC Filing
0001104659-25-013923 ↗ filed Feb 14, 2025

Holdings Value

0$100.0M$200.0M$300.0M Q1 2024: $197.9M Q1 2024 Q2 2024: $148.8M Q2 2024 Q3 2024: $153.0M Q3 2024 Q4 2024: $108.8M $108.8M Q4 2024 Q1 2025: $111.1M Q1 2025 Q2 2025: $123.8M Q2 2025 Q3 2025: $182.6M Q3 2025 Q4 2025: $229.7M Q4 2025 Q1 2026: $237.1M Q1 2026 Q2 2026: $290.2M Q2 2026

Holdings 4 stocks · $108.8M
PHVS Pharvaris NV 77.49% 4,397,881 $84.3M No change
KURA Kura Oncology Inc. 13.82% 1,726,882 $15.0M Reduce -6.7%
LYEL Lyell Immunopharma Inc. 4.90% 8,325,000 $5.3M No change
RLAY Relay Therapeutics Inc. 3.79% 1,000,000 $4.1M No change

Portfolio Sells Q3 2024 → Q4 2024
SNDX Syndax Pharmaceuticals Inc. Sold out 0.00% −11.01
KURA Kura Oncology Inc. Reduce -6.7% 13.82% −9.80

Portfolio Buys Q3 2024 → Q4 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 6$290.2MPHVS, CYTK, EIKN, RLAY, XENE
Q1 2026 8$237.1MPHVS, CYTK, EIKN, LYEL, RLAY
Q4 2025 7$229.7MPHVS, CYTK, LYEL, MAZE, RLAY
Q3 2025 6$182.6MPHVS, CYTK, MAZE, LYEL, XENE
Q2 2025 6$123.8MPHVS, MAZE, LYEL, XENE, KURA
Q1 2025 5$111.1MPHVS, MAZE, LYEL, KURA, RLAY
Q4 2024 4$108.8MPHVS, KURA, LYEL, RLAY
Q3 2024 5$153.0MPHVS, KURA, SNDX, LYEL, RLAY
Q2 2024 4$148.8MPHVS, KURA, SNDX, LYEL
Q1 2024 5$197.9MPHVS, KURA, KNTE, SNDX, LYEL